Enliven Therapeutics, Inc.
ELVN
$21.00
$0.442.14%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 27.48% | 38.65% | 48.52% | 57.93% | 56.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.30% | 20.30% | 23.61% | 31.30% | 44.94% |
| Operating Income | -13.30% | -20.30% | -23.61% | -31.30% | -44.94% |
| Income Before Tax | -14.39% | -21.33% | -18.84% | -24.04% | -37.59% |
| Income Tax Expenses | -100.00% | -100.00% | -- | -- | -- |
| Earnings from Continuing Operations | -14.07% | -20.99% | -19.14% | -24.36% | -37.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.07% | -20.99% | -19.14% | -24.36% | -37.97% |
| EBIT | -13.30% | -20.30% | -23.61% | -31.30% | -44.94% |
| EBITDA | -13.36% | -20.36% | -23.69% | -31.39% | -45.08% |
| EPS Basic | 3.18% | -3.52% | -0.19% | 12.85% | 58.72% |
| Normalized Basic EPS | 1.31% | -7.37% | -7.07% | 7.40% | 58.54% |
| EPS Diluted | 3.18% | -3.52% | -0.19% | 12.85% | 58.72% |
| Normalized Diluted EPS | 1.31% | -7.37% | -7.07% | 7.40% | 58.54% |
| Average Basic Shares Outstanding | 19.27% | 16.25% | 18.82% | 32.91% | 72.96% |
| Average Diluted Shares Outstanding | 19.27% | 16.25% | 18.82% | 32.91% | 72.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |